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SUMMARY
Macrophages from peripheral blood of leprosy patients, both multi-bacillary and paucibacillary are
unable to kill phagocytosed Mycobacterium leprae due to their inability to produce superoxide (07)
and hydroxyl radicals (OH ). The macrophages from healthy individuals are able to kill M. keprae
along with release of 07 and OH - radicals. The deficiency in the macrophages of both types of
leprosy patients is removed by activation of these cells when exposed to a culture supernatant
obtained after stimulation of peripheral blood mononuclear cells from the same patients with
delipidified cell components of M. leprae which are most likely cell wall proteins. The activation of
macrophages also leads to recognition ofwhole live M. leprae as an antigen by cells from lepromatous
patients. This activation of the phagocytes by delipidified cell components is blocked by cyclosporin
A, indicating the possible role of several steps involved in immune activation of cells. The
observations thus indicate the significant ability of delipidified cell components to eliminate the
deficiencies in the macrophages from leprosy patients and restore them to behave like the cells from
healthy individuals. Considering all these, it is suggested that delipidified cell components could be
potential modulators, and are probably capable of functioning as a vaccine for leprosy.
Keywords immunomodulation delipidified cell components leprosy killing Mycobacterium
leprae
INTRODUCTION
The importance of cell-mediated immunity in resistance to
infection caused by intracellular pathogens has been well
established. Mononuclear phagocytes clearly play primary roles
in the efferent limb of cellular control of such infections. The
microbicidal ability of phagocytes through reactive oxygen
intermediates (ROI) like hydrogen peroxide (H202), superoxide
(02) and hydroxyl radicals (OH-) is also a basic defence
mechanism of the human body against microbial infections
(Babior, Curnutte & Kipnes, 1975; Nathan et al., 1979;
Klebanoff, 1982).
Mycobacteria like M. bovis BCG (Ando et al., 1979), M.
microti (Walker & Lowrie, 1981), M. tuberculosis (Jackett, Aber
& Lowrie, 1978) and M. intracellulare (Gangadharam & Pratt,
1984) as well as M. leprae (Klebanoff& Shepard, 1984; Sharp,
Colston & Banerjee, 1985) have been shown to be susceptible to
killing by H202. There are reports that claim an inability of the
phagocytes from healthy individuals to release 02 on stimula-
tion with M. leprae (Holzer et al. 1986), yet others have reported
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that H202 and 02 are produced by macrophages of leprosy
patients in response to agents such as phorbol myristate acetate
(PMA) (Sharp& Banerjee, 1985). Nevertheless, a recent report
(Holzer et al., 1988) indicated that M. leprae are able to induce
low but significant levels of 07 in the macrophages of healthy
individuals and phagocytose the bacteria slowly.
Recently, we have reported that along with an ability to
produce 0° and H202, phagocytes from healthy individuals are
able to kill M. leprae, unlike from lepromatous leprosy patients
(Marolia & Mahadevan, 1987, 1988, 1989). The inability of M.
leprae to be killed by macrophages from lepromatous leprosy
patients was then found to be due to lack of 07 production.
Further observations made in our laboratory (Desai, Birdi &
Antia, 1989) have also confirmed M. leprae being killed by
macrophages from healthy individuals. These experiments were
independently carried out in connection with the role of
interferon-gamma (IFN-y). As well as recognizing ROI like
H202, 02 and OH as basic defence mechanism, the role of
IFN-y to stimulate macrophages to produce ROI on challenge
with infection of mycobacteria is also substantiated (Nathan et
al., 1979; Nogueria et al., 1983; Kaplan & Cohn, 1985).
We have been successful in isolating and identifying a
component ofM. keprae, the delipidified portion of the insoluble
cell components of M. leprae (DCC) as an immunomodulating
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agent. The potentialities of DCC which was obtained as an
insoluble complex have been reported in detail (Vermani &
Mahadevan, 1986; Robinson & Mahadevan, 1987).
Here we report on the comparative ability of peripheral
blood macrophages from healthy individual and different types
of leprosy patient to respond to M. leprae in relation to
production of ROI and, further, the relative ability of the cells to
kill M. leprae. Additional results are also presented to show that
stimulation of immune-deficient cells of leprosy patients by
DCC leads to activation of macrophages to kill M. leprae
through ROT. The results reported here identify the basic
deficiency leading to the tolerance of M. leprae by the cells of all
types of leprosy patients (paucibacillary and multi-bacillary)
and further indicate a method for intervention to rectify the
deficiency. The experiments also indicate the potential immuno-
modulation nature of the insoluble DCC of M. leprae.
MATERIALS AND METHODS
Patient
Leprosy patients reporting at the Acworth Leprosy Hospital,
Bombay, formed the major part of the study. The patients were
classified on the basis of the Ridley & Jopling (1966) system. The
lepromatous group was of the long-term treated (>4 years)
bacillary-negative type (B -LL). They were identified as bacter-
iologically negative, when bacilli were undetectable at multiple
skin sites and in the nose, and having had a record of regular
treatment in the clinic. The second group is the bacteriologically
positive lepromatous type untreated or undergoing treatment
(B+LL). The other group of patients were paucibacillary,
classified under the group of BT, BB.
The healthy subjects were volunteers living in the same
environment, who may have had varied exposure to M. leprae in
the city of Bombay. These healthy individuals were not close
contacts and had no regular closeness with leprosy patients.
M. leprae were obtained from infected tissues such as spleen
and liver from infected armadillo, kindly provided by Dr E.
Storrs, Florida, USA. The tissues were collected under aseptic
conditions and transported under dry ice to Bombay within a
period of 1 week. The tissues were stored at -90'C and pieces
were taken out as needed.
For obtaining host tissue-free M. leprae suspension, the
infected pieces were repeatedly rinsed in sterile normal saline, to
elute the bacilli. The suspension was centrifuged first at 500 g for
10 min to remove any larger debris and later the supernatant was
centrifuged at 4500 g for 30 min. This procedure sedimented the
acid-fast stainable bacteria. The bacterial suspension showed no
catalase activity and was thus considered as free from tissues
contaminants. Catalase is a component of host tissue and not
produced by M. leprae.
Macrophage culture from the peripheral blood was pre-
pared as reported earlier (Marolia & Mahadevan, 1989).
H202 was estimated following the method of Pick & Keisari
(1980) and adopted to mature macrophage cultures. The
method has been described earlier in detail (Marolia & Mahade-
van, 1988).
02 was estimated by the method ofSugimoto et al. (1982) as
detailed previously (Marolia & Mahadevan, 1987).
The scavengers used to remove various oxygen interme-
diates, were 2000 units of catalase (Sigma Chemical Co., St
Louis, MO) 100 pg of 02 dismutase (Sigma), 20 mm of sodium
benzoate (Ranbaxy Laboratories, India) and 1 mm thiourea
(Sisco Research Lab., Bombay, India). Since sufficient concen-
tration of these chemicals has been used, it is presumed that
effective levels were expected inside and outside the phagocytes.
Viability of M. Leprae after phagocytosis
M. leprae (25 x 106) were added to well-matured macrophage
cultures maintained in sterile Falcon dishes. After 48 h mainte-
nance of the bacteria inside the phagocytes, their viability was
determined by in vitro and in vivo methods. In 48 h more than
75% of the cells from leprosy patients have M. leprae inside, and
on an average 50-60% of the cells have more than 10 bacilli. In
the phagocytes ofhealthy individuals more than 50% of the cells
showed phagocytosis with an average of 5-20 bacilli in majority
of them.
Viability of M. leprae inside the macrophages was deter-
mined using fluorescein diacetate (FDA) staining method
described earlier (Mahadevan et al., 1986; Bhagaria & Mahade-
van, 1987; Marolia & Mahadevan, 1989), a modification of that
described by Kvach, Mungia & Strand (1984). The cells
containing M. leprae were scraped off the Petri dishes and
suspended in 1 ml of 1 M saline. The suspension was subjected to
12 cycles of freeze-thawing. The lysate so obtained was
centrifuged at 500 rev/min to pellet the cell debris. The
supernatant containing M. leprae was centrifuged at 5000 g for
30 min. The M. leprae pellet was resuspended in 1 ml of saline.
Three loopfuls each of 0 001 ml were spread on a glass slide
within a diameter of 16 mm. The suspension was air-dried and a
drop of the staining solution was placed on it. The staining
solution consisted of 4 yg/ml FDA and 4 yg/ml ethiolium
bromide in phosphate-buffered saline (PBS). A cover-slip was
placed on it and the edges were sealed with nail polish to avoid
drying of the solution. The preparation was incubated for 40
min in the dark. The slide was then observed under incident u.v.
light using a blue excitation filter on a Fluoval II Fluorescence
microscope at a magnification of x 400. By using this modified
method, the entire population of the bacteria phagocytosed
could be stained by FDA and also as AFB by Ziehl Neelson's
method. The quantum of viability was expressed as percent
green fluorescing bacilli in a total AFB population. The entire
slide spot is scanned and all bacilli counted; this could yield 800-
1000 bacilli. We have not considered those bacilli with indeter-
minate staining.
Loss of viability of M. leprae phagocytosed by mature
macrophages was also determined by recovering the bacilli after
the necessary incubation inside the cells and testing their ability
to grow in the foot-pads of mice. The recovery of the bacilli was
done after 10 cycles of freeze-thawing and centrifugation. The
bacterial suspension of 1 x 104 bacilli was used and the growth
obtained at 8 months and 12 months post-inoculation was
determined. Counting bacillary load in the foot-pad was
performed according to Shepard & McRae (1965). This test was
specifically done to correlate the loss of viability along with the
production of superoxide ions. We did not follow the method to
determine the maximum viable number of bacilli in the test
samples, but determined the growth at various harvest periods.
In all experiments where bacteria were obtained by freeze-
thawing, loss of viability due to this technique itself could be
determined by comparing the viability of original bacillary
suspension used for phagocytosis. This is determined in a smear
preparation and data are reported along with other results.
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Preparation of DCC-stimulated culture supernatants
DCC of M. keprae was prepared by the method reported by
Robinson & Mahadevan (1987) and used from the stock
suspension available in the laboratory. Basically, it was the
insoluble residue obtained after prolonged sonication of M.
leprae and delipidified repeatedly to remove the wall-associated
lipids. It was prepared as follows: M. leprae were separated from
infected armadillo tissues, washed with saline twice, and 10'°-
10" cells/5 ml suspension of the bacilli were prepared in saline.
The cells were sonicated in a soniprep (MSE) ultrasonicator at
40C with 5-min pulse followed by 5-min rest for 5 h at a power of
55 W using a 9-5-mm probe. The sonicate was subjected to
differential centrifugation as described by Rastogi & David
(1981), with modifications. The crude cell wall was then
delipidified by extraction with Cl: M (2: 1) (three times) for 15
min at room temperature (Folch, Lees & Stanley, 1957)
(DCC-I). This fraction was further delipidified by extraction
with acetone (three times) and ethanol: ether (1: 1) three times
for 15 min at room temperature (Robinson & Mahadevan,
1987). The resulting insoluble and sedimented DCC (DCC-II)
obtained as a pellet was then suspended in saline and sonicated
for 5 min at an amplitude of 14 in order to get a homogenous
suspension. The protein content of the DCC was estimated by
the method of Lowry et al. (1951). The material was kept sterile
during the processing and recovery. Since some essential
features typical of cell wall components of M. leprae have not
been tested in this insoluble preparation, it is referred to as DCC
but was earlier referred to as delipidified cell wall (DCW).
Mononuclear cells were separated over Ficoll-Triosil (Lym-
phoprep-Nyegaard, Oslo, Norway) density gradient and the cell
count was determined. The cell suspension was adjusted to
I x 106 cells/ml in culture medium (MEM+20% human AB
serum) and distributed in Petri dishes. One set of culture was
stimulated with DCC (400 pg as protein for I x 106 cells).
Incubation was carried out for 96 h at 37°C in 5% CO2
atmosphere. The culture supernatant was obtained by filtration
(Millex filter 0 22 pm). The supernatant referred to as 'DCC-
stimulated supernatant,' was stored at - 20°C till further use; it
used within 4 days, to avoid possible loss of stimulatory activity.
Such preparation could be made by using the peripheral blood
mononuclear cells from any type of leprosy patients.
Lymphocyte proliferation assay
Blood collected under sterile conditions from the subjects was
used to prepare mononuclear cells. These cells were separated by
centrifuging the blood over Ficol-Triosil (Lymphoprep) gra-
dient. Lymphocyte proliferation using 3H-thymidine (specific
activity 9-8 pCi/mmole) was performed as previously reported
(Robinson & Mahadevan, 1987).
Loss of viability ofM. leprae in macrophage cultures exposed to
DCC-stimulated culture filtrate
To the mature macrophage culture, I ml of DCC-stimulated
culture supernatant (from the same patient) was added and
incubated for 24 h at 37°C. At the end of the incubation period,
the medium was aspirated and fresh medium along with M.
leprae (25 x 106) was added. At that time different treatments
(addition ofcatalase, 02- dismutase, sodium benzoate, thiourea,
etc.) were carried out and phagocytosis was allowed for 48 h at
37°C in 5% C02 atmosphere. The cultures were terminated,
bacilli were released by freeze-thawing as described earlier and
viability determined by the methods mentioned before. In
parallel cultures, ROI released were also determined with
special reference to 02- after exposure of M. leprae to the cells
for 3 h.
Role of cyclosporin A
Macrophage cultures were set up as indicated earlier from a
patient. At the same time, DCC-stimulated supernatant was
produced from the same patient in presence and absence of
cyclosporin A (5 jpg/ I x 106 cells). The supernatant was collected
after 4 days of incubation, filtered and stored. Seven-day-old
macrophages from the same patient were exposed to the above
culture supernatant for 24 h, and the supernatant was then
removed. M. keprae was added and after 3 h stimulation 02- was
estimated. In separate experiments the role of the DCC-
stimulated supernatants as prepared above were also tested on
the killing of M. keprae.
Statistical analysis
Results are expressed as mean + s.d. and statistical significance
was determined by Student's t-test.
RESULTS
The mature macrophages from the peripheral blood of healthy
individuals are able to produce substantial levels of H202 (111
nmoles/h per 106 cells) and 02 (2-2 nmoles/h per 106 cells), when
Table 1. Correlation between reactive oxygen intermediates and loss of viability of Mycobacterium leprae inside the
macrophages of leprosy patients and healthy individuals
Tuberculoid
B+LL B-LL leprosy Healthy
02- dismutase removable superoxide (nmol/h per 106 cells) 0 3+±03 0 3+±02 0 2+0 3 2 2 +0 5
H202 (nmol/h per 106 cells) 25 0+ 15 89 0+2 6 62 9+ 10-1 1112 + 10 5
Original smearviability (% viability ofM. leprae in suspension) 530±+ 9 7 48 0+ 16 3 55 5 + 9 0 56 2+ 10 6
Viability of M. leprae inside the macrophage (%) 620+ 16 6 505+19-0 59 2+9-6 21.0+8.5*
All values are mean of five separate experiments.
*P<0-05
B + LL, bacillary-negative lepromatous leprosy; B -LL, bacillary-negative lepromatous leprosy.
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Table 2. Superoxide production (nmol/h per 106 cells) by macrophages from various types of individuals exposed to Mycobacterium
leprae and influence of DCC-stimulated supernatant (mean± s.d.)
B-LL B+LL Tuberculoid Healthy
(n = 7) Difference (n = 7) Difference (n = 3) Difference (n = 3) Difference
Control MO
(no M. leprae added) 4 0+0 5 3-4+0-4 2-4+0-6 5 2+0 8
M1 heat-killed M. leprae 7-6+1 0 3 8 +0-2 4-4+0-6 95+ 1 6
35 03 2-1 2-2
MP+ heat-killed
M. leprae+OZ dismutase 41 +0 3 3 5+0 3 2-3+0-6 7 3+ 1-4
MD+live M. Ieprae 4-1+0 4 3 5+0 3 2-3+0-8 7 8+1-3
04 01 0-1 1-7
(A) (C)
MO+liveM.keprae+O dismutase 3-7±+06 3 4+0 3 2-2+0-7 6-1 + 1-0
M4+ DCC-stimulated supernatant 5 0+ 0-8 3 4+007 2-8 +0 8 6-1 +0-8
MO+ DCC-stimulated
supernatant+live M. keprae 7 0+0-8 5 0+0 4 4-2+0-6 10-1+2-6
28 20 1-7 24
(B) (D) (E)
M1 + DCC-stimulated supernatant
+live M. leprae+°2 -dismutase 4-2+0-8 3 0+0 4 2-5+0 7 7-7+ 1-7
* The differences indicate superoxide dismutase removable superoxide.
A versus B, P< 0-05; C versus D, P < 0-05; B versus E, P=0 05 not significant.
D versus E, P= 005 not significant.
DCC, delipidified cell components; MO, macrophage.
Table 3. Viability ofMycobacterium leprae as determined by FDA staining method inside the macrophages
from various individuals on exposure to DCC-stimulated supernatant and in relation to production of
reactive oxygen intermediates (mean + s.d.)
B- LL Tuberculoid B+ LL Healthy
(n = 7) (n = 6) (n= 6) (n = 4)
M4+live M. leprae in culture (A) (B) (C) (D)
505+ 19-0 542+96 62-0+ 166 8-2+ 18
MO+DCC supernatant M. leprae (E) (F) (G)
146+145 19 1+8-4 233+86 3-6+1 7
M1+DCC supernatant+ M. leprae+°2 dismutase 29-0 +16 0 273 + 88 255 + 21 27-7 + 13-3
M4 +DCC supernatant+M. leprae+catalase 30 0+ 18 7 34 5+ 15 6 25-0+4-2 29-3+21 4
MO+DCC supernatant+ M. leprae+ 02 dismutase (H) (I)
+ Catalase 56-5+335 42 3 + 6-7 32-0
Original viability of M. leprae before phagocytosis (K)
48 0+6 3 55 5+9 0 53 0+9 7 33-8+ 13 2
B-LL, bacillary-negative lepromatous leprosy; B+LL, bacillary-positive lepromatous leprosy; MO,
macrophage; DCC, delipidified cell component; A versus D, P< 0-05; B versus D, P < 005; C versus D,
P< 0 05; A versus E, P< 0-05; B versus F, P< 0 05; C versus G, P< 0-05; A versus H, P< 0 05 (NS); B versus
I, P= 0 05 (NS); D versus K, P < 0-05.
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Table 4. Correlation of superoxide production and loss of viability of Mycobacterium leprae inside macrophages of normal
healthy individuals by FDA method and correlated with the ability ofthe phagocytosed bacteria (1 x 104) to grow in the foot-
pads of mice
Viability of M. leprae inoculated in
Viable the foot-pad of mice (average of four
Superoxide M. leprae foot-pads) at harvest (months)
production (FDA test)
(nmol/h per 106 cells) (%) 6 8 10 12
Control macrophage 5-0
Macrophage+live M. leprae 90) 60 no AFB no AFB no AFB no AFB
Macrophage+live M. leprae+02 dismutase 6 5 16 0 9.0 x 104 6 0 x 104
Macrophage+live M. leprae+Catalase 16 6 - 225 x 10 - 2 1 x 105
FDA, fluorescein diacetate; AFB, acid fast bacilli.
* Difference, 02 dismutase removable superoxide.
Table 5. Viability of Mycobacterium leprae in the foot-pad of mice after phagocytosis by
macrophages from paucibacillary leprosy patients in the presence of DCC-stimulated
lymphokines with or without cyclosporin A
Month 6 Month 7 Month 8
M. leprae from control macrophages
(no other treatment) 1-5 x 10' 1 57 x 105 2-1 X 105
M. leprae from macrophages exposed
to DCC stimulated from same patient No AFB seen No AFB seen No AFB seen
M. leprae from macrophages exposed
to DCC stimulated from same patient
and prepared in the presence ofcyclosporin A 6 x 104 1-35 x 105 4-5 x 105
Only two growth and harvest periods were obtained.
DCC, delipidified cell component.
challenged with live M. leprae. However, the phagocytes from
patients could also respond to M. leprae by producing H202,
although to a lesser extent, compared with individuals. How-
ever, these cells produced negligible levels of 02 dismutase
removable 02 .Table I shows a loss of viability of M. keprae
inside the cells from healthy individuals, associated with 02- and
H202. The M. keprae used for the experiments showed an
average viability of56% in smear preparation by FDA method.
However, phagocytosis of the same by the cells resulted in a
viability of21% (on an average) inside the mature macrophages.
This indicated a statistically significant loss in viability
(P < 0 05).
The viability of M. leprae after phagocytosis by the cells of
all types of leprosy patients was as good as the viability of bacilli
used for the experiment with the cells from such leprosy patients
(smear preparation, 48-55%, compared with 50 5-62% after
phagocytosis).
The results presented in Table 2 indicate that in the presence
of DCC-stimulated culture supernatant the macrophages from
all three groups ofpatients could get stimulated to release 07-. In
the case of healthy individuals the culture supernatant could
only further enhance the production of 02, which was already
induced in any case by live M. leprae itself. Thus it was observed
that when the supernatant of culture fluid in which the deficient
cells from patients were exposed to DCC was added to the same
patient's phagocytes, the cells responded well to live M. leprae
by producing 027
It was also demonstrable (Table 3) that along with the 02
produced in the deficient cells on exposure to the culture
supernatant, there was also a reduction in viability of M. keprae
phagocytosed by the macrophages. The viability of M. leprae
inside the macrophages was reduced from 50 5% to 14-6% in the
macrophages from B-LL patients. The viability of M. Ieprae in
the macrophages of tuberculoid leprosy or paucibacillary
patients was high (54-2%) compared with the original smear
viability of 55 5% indicating a lack of killing ability of these
cells. In presence of the DCC-stimulated culture supernatant, a
drop in viability was seen (19 1%). The importance of 02 and
H202 was further indicated, since treatment with 02 dismutase
along with catalase prevented the loss of viability of M. keprae
inside the macrophages. Similar type of observations were seen
with macrophages from B+LL patients as well. The macro-
phages of healthy individuals have an in-built defence mecha-
nism, since they show a normal respiratory burst activity. So the
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Table 6. The ability of lymphocytes from B+LL patients to respond to Mycobacterium
leprae as an antigen in the presence of lymphokines generated by the same cells on
stimulation with DCC
Stimulation index*
Experiment Experiment Experiment
Antigen used in presence of PBMC 1 2 3
Live M. leprae 1 13 1 0 1.0
DCC of M. leprae 2 57 2 36 1 68
Control lymphocyte
supernatant+live M. leprae < 1 0 1 06 < 1 0
Lymphokines from DCC
exposure+ live M. leprae 2 12 2-0 1-98
Lymphokines from DCC exposure with
live M. leprae and cyclosporin < 1 0 1.0 < 1.0
B+LL, bacillary-negative lepromatous leprosy; DCC, delipidified cell components;
PBMC, peripheral blood mononuclear cells.
* Calculated as:
average d/min (triplicates) of experimental value
average d/min (triplicates) of control values
Table 7. Ability of macrophages from B- LL patients to release 02 in response to Mycobacterium leprae after treatment with DCC-
stimulated supernatant prepared in presence and absence of cyclosporin A
Amount of superoxide released
Viability
n mol/h 106 cells) Mean* (%)t
Control M4I (no M. leprae added) 2-5 3 7 2-5 3 1 2-95
MO+ live M. leprae 31 3-7 2 8 4 5 3 50 613
MO+heat-killed M. leprae 5 9 6-0 6 9 7-1 6-47
MO +DCC-stimulated supernatant+live M. leprae 6 4 5-7 7 1 6-4 6-4 16 3
MI + DCC-stimulated supernatant + liveM. leprae+02 dismutase 33 3-2 23 32 30
Differencet 3 1 2-5 4 8 3-2 3 4
MF + DCC-stimulated supernatant prepared in presence of
cyclosporin A+live M. leprae 3 4 3-2 2 3 3-2 3-02 59 3
Mb + DCC-stimulated supernatant prepared in presence of
cyclosporin A+live M. leprae+02 dismutase 3 1 3-2 - 315
Difference 0 3 00
B -LL, bacillary-negative lepromatous leprosy; DCC, delipidified cell components; MO, macrophage.
* Average of four experiments
t Average value of three separate experiments.
I 02 dismutase removable 02 .
role of DCC stimulated supernatant was not of further signifi-
cant effect, even though there was further reduction in viability.
The loss of viability of M. keprae inside the macrophages of
healthy individuals and the B-LL patients and paucibacillary
individuals was also tested by recovering the phagocytosed
bacteria 48 h after phagocytosis and injecting I x 104 of these
bacilli in the foot-pads of Swiss white mice. This was compared
with M. leprae obtained under various conditions of treatment
of the macrophages.
Table 4 shows that M. leprae obtained after incubation
inside the macrophages showed no growth in the harvest periods
of 6, 8, 10 and 12 months. However, those bacteria phagocy-
tosed by macrophages and maintained in presence of 02
dismutase or catalase did show on harvest at month 8 and 12,
indicating survival of the phagocytosed M. leprae and thus
viability of the infected bacilli. Since we found no growth in any
harvest periods in the control group, it was likely that there was
total loss of viability after phagocytosis of M. leprae. Yet, M.
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leprae derived from cells of leprosy patients after phagocytosis
showed no loss of viability as tested in the foot-pad (data not
presented).
In a similar experiment, using macrophages from pauciba-
cillary patients, it was demonstrated (Table 5) that macrophages
on their own allow viability of M. leprae, but those cells exposed
to DCC-stimulated supernatant showed loss of viability of M.
leprae phagocytosed by them. This loss of viability was not seen
when the cultures were exposed to DCC-stimulated supernatant
prepared in presence of cyclosporin A and the M. keprae
phagocytosed under that condition did not lose viability.
In the B+LL patients, when the DCC-stimulated superna-
tant was added to the same patients' lymphocytes, these cells
which do not normally respond to M. leprae antigen responded
very well to M. keprae by showing a lymphocyte proliferation
(Table 6). This lymphocyte proliferation indicated a modulation
of the B+LL cells for LTT after the addition of the supernatant.
Table 7 shows that cyclosporin A appears by its presence to
block the production of an active DCC-stimulated supernatant.
The supernatants produced in presence of cyclosporin A and
DCC were not capable ofmodifying the phagocytes to recognize
M. keprae and produce 07, and also to kill the phagocytosed
bacteria. In the absence of cyclosporin A, DCC supernatant
enabled the cells to produce 3-1 nmol/h per 106 cells 02 and to
induce killing from 613% viability to 16-3%. However, in
presence of cyclosporin A, no 02 was produced, and viability
was not reduced.
The activation of deficient macrophages by DCC-stimulated
cell supernatant was tested after preparation of supernatants in
the presence of cyclosporin A. Data presented in Table 7 shows
supernatant prepared in presence of cyclosporin A had no
ability to activate the macrophages to respond to live M. leprae
with production of 02, nor the ability to kill the phagocytosed
M. keprae.
DISCUSSION
Our own results reported earlier (Marolia & Mahadevan, 1987,
1988, 1989) and the results of others (Desai et al., 1989) have
now indicated that healthy individuals from a leprosy-endemic
city like Bombay are capable of killing M. leprae through ROT.
Since this process is blocked by sodium benzoate or thiourea, as
well as by 02 dismutase along with catalase, one could implicate
OH radicals as most effective ones. We have not assessed as yet
role of metal ions like iron in this function. It is also indicated
that H202 on its own is least effective, since in leprosy patients
H202 production does not lead to loss of viability. Thus H202
needs some other component to be effective. 02 fits in well with
this requirement, as discussed earlier (Marolia & Mahadevan,
1987, 1988).
The tolerance of M. Ieprae by the macrophages of all types of
leprosy patients is quite similar to what is observed in vivo. One
could appreciate this feature in lepromatous type, but in
paucibacillary cases it has been repeatedly mentioned that the
bacilli are killed. It was obvious from our data presented here
and from our earlier observations (Marolia & Mahadevan,
1987, 1988), that in paucibacillary patients, killing mechanisms
was not through ROI as seen in healthy individuals. The
protective mechanism then could be due to cell-mediated
immunity leading to activation of macrophages. This point
needs further elucidation in paucibacillary cases. Nevertheless,
our data clearly indicated the reason for transitory survival of
M. keprae in paucibacillary leprosy patients. In lepromatous
patients the cells showed no ability to produce ROI or kill M.
keprae. It is noteworthy that long term treated lepromatous
patients do not recover the ability to produce 02 and kill M.
leprae even after prolonged treatment. This could thus indicate a
pre-existing inefficient nature in the patient in handling M.
leprae. When the individual is carrying bacteria as in B+LL, the
cells exhibit still more deficiency parameters, that lead to no
response at all to produce even sufficient H202 to M. leprae and
also 02 even to killed M. leprae.
The deficiency noted in the leprosy patients in relation to
ROI was further confirmed by modifying the deficiency using
the earlier identified (Vermani & Mahadevan, 1986; Robinson
& Mahadevan, 1987) immunomodulator, DCC. We had
reported that DCC-stimulated supernatant obtained from
peripheral blood mononuclear cells of a patient could induce
killing of M. leprae in the phagocytes of the same patient. Our
present results clearly indicate that DCC-stimulated superna-
tant are able to modify the phagocytes to respond to M. keprae in
several ways. Some of them are documented by our observa-
tions. The DCC-stimulated supernatants alter the phagocytes to
recognize M. leprae as an antigen and initiated in vitro
lymphocyte proliferation. The phagocytes were also made to
recognize M. keprae to produce 02 which in turn inactivated the
phagocytosed M. leprae. Both these features which were not
demonstrable in the cells of lepromatous leprosy patients,
bacteriologically positive or negative, are thus exhibited as in the
healthy individuals. In the case ofpaucibacillary patients, ability
to kill M. leprae was restored as in the healthy individuals. It is
interesting that production of an active DCC-stimulated super-
natant and lymphocyte proliferation by cells of leprosy patients
are blocked by cyclosporin A. Cyclosporin A is reported to
block antigen presentation, lymphocyte activation and lym-
phokine production (Palay et al., 1986; Varey, Champion &
Cooke 1986). From our observations it can be assumed that
DCC could be presented as antigen, and that following
lymphocyte activation there could be release of useful lympho-
kines. Recent observations of Robinson & Mahadevan (perso-
nal communication) have confirmed this assumption.
Thus, our very early observation regarding the importance
of delipidified cell wall (Khandke, Salgame & Mahadevan,
1984) and other reported data (Vermani & Mahadevan, 1986;
Robinson & Mahadevan, 1987) as well as the recently reported
results of Kaplan et al. (1988) indicating a role for cell wall
proteins as good T cell activating antigens, all point to the
importance of delipidified cell wall components.
It seemed that the in vitro stimulation by the complex
insoluble antigen from M. leprae (probably as a subunit)
endowed a status to the immune-deficient cells of both pauciba-
cillary and multi-bacillary leprosy patients to behave as cells
from healthy individuals. Such a modification leads to recogni-
tion of live M. leprae, followed by phagocytosis and killing. It
may be suggested that this could be the mechanism to induce
modulation by any vaccine to be effective in both types of
leprosy. If this is so, the DCC has a definite potential for testing
as a vaccine in humans. In experiments with mice vaccinated
with DCC, activation of the peritoneal macrophages to kill M.
keprae through increased ROI was observed. Such a mechanism
was absent in non-immunized mice (unpublished data). Taken
together, these observations and those of our earlier reports
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(Vermani & Mahadevan, 1986; Robinson & Mahadevan, 1987;
Marolia & Mahadevan, 1989), seem to indicate that DCC ofM.
leprae, which is a complex set of proteins probably from the cell
wall, has definite potential as a potent modulator for multiba-
cillary as well as paucibacillary leprosy.
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